1. Home
  2. KNSA vs CCU Comparison

KNSA vs CCU Comparison

Compare KNSA & CCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CCU
  • Stock Information
  • Founded
  • KNSA 2015
  • CCU 1850
  • Country
  • KNSA United Kingdom
  • CCU Chile
  • Employees
  • KNSA N/A
  • CCU N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CCU Beverages (Production/Distribution)
  • Sector
  • KNSA Health Care
  • CCU Consumer Staples
  • Exchange
  • KNSA Nasdaq
  • CCU Nasdaq
  • Market Cap
  • KNSA 1.7B
  • CCU 2.0B
  • IPO Year
  • KNSA 2018
  • CCU 1992
  • Fundamental
  • Price
  • KNSA $21.09
  • CCU $11.07
  • Analyst Decision
  • KNSA Strong Buy
  • CCU Hold
  • Analyst Count
  • KNSA 5
  • CCU 3
  • Target Price
  • KNSA $36.60
  • CCU $11.91
  • AVG Volume (30 Days)
  • KNSA 365.7K
  • CCU 114.8K
  • Earning Date
  • KNSA 10-29-2024
  • CCU 11-06-2024
  • Dividend Yield
  • KNSA N/A
  • CCU 3.29%
  • EPS Growth
  • KNSA N/A
  • CCU 16.02
  • EPS
  • KNSA N/A
  • CCU 0.39
  • Revenue
  • KNSA $384,098,000.00
  • CCU $2,795,960,314.00
  • Revenue This Year
  • KNSA $60.05
  • CCU $6.59
  • Revenue Next Year
  • KNSA $36.32
  • CCU $5.74
  • P/E Ratio
  • KNSA N/A
  • CCU $14.51
  • Revenue Growth
  • KNSA 54.41
  • CCU N/A
  • 52 Week Low
  • KNSA $15.52
  • CCU $10.00
  • 52 Week High
  • KNSA $28.15
  • CCU $13.74
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 34.36
  • CCU 50.54
  • Support Level
  • KNSA $20.41
  • CCU $10.89
  • Resistance Level
  • KNSA $21.55
  • CCU $11.08
  • Average True Range (ATR)
  • KNSA 0.87
  • CCU 0.21
  • MACD
  • KNSA -0.14
  • CCU -0.00
  • Stochastic Oscillator
  • KNSA 21.90
  • CCU 47.73

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CCU Compania Cervecerias Unidas S.A.

United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.

Share on Social Networks: